Navigation Links
Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
Date:9/11/2007

- Additional Phase 3 Trials on Track for Initiation Later This Year -

- Conference Call Scheduled for Today at 8:30 a.m. Eastern Time -

SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that an independent Echocardiographic Data Safety Monitoring Board (the Board or EDSMB) found no reason to stop the ongoing pivotal Phase 3 trial, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management). The BLOOM trial is evaluating the efficacy and safety of lorcaserin hydrochloride for the treatment of obesity. The findings of the Board were based on a planned detailed review of unblinded echocardiograms performed after patients completed six months of dosing in the trial. The review was conducted by the Board and confirms that differences, if any, in the rates of U.S. Food and Drug Administration (FDA)-defined valvulopathy in patients treated with lorcaserin and in the control group did not meet predetermined stopping criteria. The review also confirmed that the rate of FDA-defined valvulopathy in the placebo group is consistent with the company's statistical powering assumptions used in the design of the pivotal trial program to monitor patients for any increased risk of developing valvulopathy. Arena is currently in discussions with the FDA to finalize protocols for two additional Phase 3 pivotal trials scheduled to begin later this year.

"Patient safety is and always has been a primary focus for Arena in our effort to fully explore and understand lorcaserin's profile and its potential to safely help a significant number of patients that are obese or overweight improve their health by better managing their weight," said Jack Lie
'/>"/>

SOURCE Arena Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Traveling stem cell show continues state tour
4. AT&T - BellSouth merger: Revestiture continues
5. Madison biotech continues its climb
6. Brady continues growth through Asian acquisition
7. Transition continues to impact Third Wave financials
8. Line between big pharma, big biotech continues to blur
9. Wisconsin giant continues to dominate the health care IT market
10. API Software continues expansion
11. Third Wave continues molecular diagnostic focus with new CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces the ... office space for Shire a leading biopharmaceutical company, at Two ... | RBJ,s Robert Richards , president, and Brian ... for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... The laboratory information management systems market is ... of technological advancements due to factors such as rising ... integrate healthcare systems, and increasing government support for adoption ... Key players in the market focus on technological advancements ...
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics ... from a new partner. STT-Systems has developed an ... years, with offerings in the optical-motion capture, 3D scanning, and ... measurement unit), iSen, is opening eyes around the world. With ...
(Date:1/22/2015)... Diagenode, Inc., a leading global provider ... complete solutions for epigenetics research, recently launched a ... need for manual processing. The new ChIPettor System ... histones or transcription factors and a semi-automated pipette ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... - Worldwide Net Revenue Increased 4% for the 2008 Third Quarter and ... - Third Quarter Revenue Growth in Pharmaceuticals Division Led by ... and Prevnar +13% , - Guidance for 2008 Full ... Items, Revised to a Range of $3.49 to $3.55 , ...
... - Updated Results Presented at 20th EORTC-NCI-AACR ... and GENEVA, Oct. 22 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, ... focused on oncology, today announced positive incremental ... of picoplatin in combination with,docetaxel and prednisone ...
... of Health, SAN DIEGO, Oct. 22 ... $28 million contract from the National Institute,of Allergy ... National,Institutes of Health, for the development of novel ... five-year,contract, Trius will develop novel drugs targeting bacterial ...
Cached Biology Technology:Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 2Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 3Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 4Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 5Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 6Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 7Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 8Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 9Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 10Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 11Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 12Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 13Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months 14Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 2Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 3Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 4Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 5Trius Awarded $28 Million Contract to Develop Novel Antibiotics 2
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced the ... Security Systems Market" report to their offering. ... perimeter security market is estimated to grow at a CAGR ... holds a larger share in this market, Canada ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 The ... it easier to detect and prevent counterfeit microcircuits from ... agency started performing an in-house microcircuit anti-counterfeit initiative dubbed ... purchased microcircuits while increasing their reliability throughout the supply ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... sandpipers ( Calidris pusilla ) feeding during low tide ... Beauchamp, an ornithologist and research officer at the University ... the periphery remained alert and used short pecks to ... the group relaxed their vigilance and fed on a ...
... are the heart of the smaller, better electronics ... new materials, medical diagnostics and therapeutics, energy storage, ... have unintended consequences for human health and the ... and policy makers, the Virginia Tech Center for ...
... long lasting, possibly permanent, performance-enhancing effects, shows a study ... Physiology ., Previously, re-acquisition of muscle mass with ... has been attributed to motor learning. However, this new ... is a cellular ,memory mechanism, within muscle of brief ...
Cached Biology News:Bird buffet requires surveillance 2Nanomaterials database improved to help consumers, scientists track products 2Nanomaterials database improved to help consumers, scientists track products 3Nanomaterials database improved to help consumers, scientists track products 4
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
... Super Sensitive MultiLink IHC Detection ... secondary antibodies, labeled with multiple ... the bound primary antibody, and ... Streptavidin-Enzyme conjugate. This kit is ...
BioGenex IHC Kits for Rodent Tissues are designed for immunohistochemistry on rodent and rabbit tissues that are closely related to the source of the primary antibody. This kit comes with rat seconda...
Dual-bay Dyad thermal cycler chassis, does not include the Alpha units (requires 2)...
Biology Products: